Key Takeaways:
- $250 Million Milestone Deal: Chugai secures global rights to develop and commercialize novel antibody therapies for age-related diseases using targets identified by Gero’s AI-driven platform.
- AI Meets Antibody Innovation: Gero’s human data-first AI approach converges with Chugai’s proprietary antibody engineering to accelerate discovery of first-in-class anti-aging therapies.
- Longevity Therapeutics in Focus: The collaboration could set a new benchmark in AI-guided drug discovery for complex, systemic diseases linked to aging.
AI-Powered Target Discovery Meets World-Class Antibody Engineering
The joint research and license agreement between Tokyo-based Chugai Pharmaceutical Co., Ltd. and Singapore-based Gero marks a significant industry milestone in applying artificial intelligence to therapeutic innovation. Gero’s platform, which decodes human biological aging through high-dimensional data and machine learning, will provide novel targets that Chugai will translate into cutting-edge antibody drugs using its proprietary engineering technologies. This partnership is designed to unlock therapeutic approaches for multiple age-related diseases and conditions that remain underserved by current treatments.
Global Rights, Long-Term Vision, and a $250M Opportunity
Under the agreement, Chugai obtains exclusive worldwide rights to develop, manufacture, and commercialize therapies directed at AI-identified targets. In addition to an upfront payment, Gero stands to receive up to $250 million in development and sales milestone payments, along with tiered royalties. This deal underscores the long-term commercial and therapeutic potential of combining data-centric discovery with biologic innovation. The collaboration aligns with Chugai’s “TOP I 2030” strategy, which emphasizes open innovation and global-first drug discovery.
Targeting the Biology of Aging—Not Just Symptoms
Gero’s AI platform is uniquely designed to identify key molecular drivers that accelerate aging and contribute to multiple degenerative conditions. Unlike traditional drug discovery that focuses on isolated disease symptoms, Gero’s approach aims at the biological roots of aging. Chugai’s application of this intelligence to its antibody platform could result in a new class of first-in-class or best-in-class therapies aimed at restoring lost function, improving resilience, and extending healthspan. This paradigm shift could open doors for treating multimorbidity with a single mechanism-based strategy.
Transforming Drug Discovery Through Deep Tech Partnerships
This alliance reflects a broader transformation in how pharmaceutical companies approach R&D in the AI era. By forging data-technology-biopharma synergies, Chugai and Gero are pioneering a model where human health data, AI prediction, and advanced biologics development intersect. With aging populations driving demand for innovative healthcare solutions, this collaboration is timely and poised to reshape the therapeutic landscape for age-associated diseases.
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, is a Tokyo-based, research-driven biopharmaceutical company with world-class capabilities in antibody engineering and biologic innovation. With a focus on addressing unmet medical needs, Chugai combines proprietary drug discovery platforms with cutting-edge science to develop breakthrough therapies across oncology, immunology, and other key disease areas. As part of its global-first strategy, Chugai is committed to delivering advanced, sustainable, and patient-centric healthcare solutions.
About Gero PTE. LTD.
Gero PTE. LTD. is a Singapore-based, AI-driven biotechnology company dedicated to extending healthy human lifespan through the development of therapies that target the biology of aging. Leveraging physics-based machine learning and vast human data sets, Gero’s proprietary platform identifies high-impact therapeutic targets driving age-related diseases. Focused on translating deep biological insights into disease-modifying therapeutics, Gero partners with leading pharma innovators to transform how aging and degenerative conditions are treated globally.
By
